PExA offers a patented, non-invasive technology to collect biomarkers from the small airways of the lung via exhaled air. The method is used globally by universities, hospitals, pharmaceutical companies, CROs and government agencies in the US and Europe, among others – in research on asthma, COPD, lung cancer, occupational exposure and pharmacokinetics. The company's goal is to enable earlier diagnosis and screening of lung diseases. PExA was founded in 2014 and is headquartered in Gothenburg.